Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.66 |
| ▸ | NPC1 | O15118 | 4/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | RAB9A | P51151 | 3/20 | 0.60 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.60 |
| ▸ | KDR | P35968 | 1/20 | 0.60 |
| ▸ | FLT3 | P36888 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | GLA | P06280 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | BCHE | P06276 | 1/20 | 0.49 |
| ▸ | PTGES | O14684 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | BIRC5 | O15392 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5225670 | 0.93 | NPC1 (0.60) | TLR9NPC1SMN1; SMN2RAB9APDGFRB | |
| SCHEMBL7600391 | 0.89 | TLR9 (0.51) | TLR9NPC1SMN1; SMN2RAB9APDGFRB | |
| SCHEMBL7601150 | 0.82 | NPC1 (0.47) | TLR9NPC1SMN1; SMN2RAB9APDGFRB | |
| SCHEMBL30882145 | 0.82 | TLR9 (0.70) | TLR9NPC1SMN1; SMN2RAB9APDGFRB | |
| SCHEMBL22661774 | 0.82 | TLR9 (0.70) | TLR9NPC1SMN1; SMN2RAB9APDGFRB | |
| SCHEMBL20928216 | 0.81 | BCHE (0.53) | TLR9NPC1SMN1; SMN2RAB9APDGFRB | |
| SCHEMBL973317 | 0.80 | NPC1 (0.68) | TLR9NPC1SMN1; SMN2RAB9APDGFRB | |
| SCHEMBL30786723 | 0.80 | NPC1 (0.68) | TLR9NPC1SMN1; SMN2RAB9APDGFRB | |
| SCHEMBL7202685 | 0.79 | NPC1 (0.66) | TLR9NPC1SMN1; SMN2RAB9AALDH1A1 | |
| SCHEMBL16687607 | 0.79 | NPC1 (0.70) | TLR9NPC1SMN1; SMN2RAB9APDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101103026-A | Bicyclic heteroaryl derivatives for treating viruses | GENELABS INC (US) | 2008-01-09 | — | — | CN | disclosed |
| EP-1844042-A1 | INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2007-10-17 | — | — | EP | disclosed |
| US-20060211698-A1 | Bicyclic heteroaryl derivatives for treating viruses | GENELABS, INC. | 2006-09-21 | — | — | US | disclosed |
| WO-2006076529-A1 | INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211698-A1 | Bicyclic heteroaryl derivatives for treating viruses | HAVCR2, ZC3HAV1, SARS1 | TLR9 3069/4885NPC1 153/4885SMN1; SMN2 2173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.